CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)
Grant income	$ 0	$ 558,664
Operating expenses:
Research and development	23,108,897	17,840,290
General and administrative	13,085,232	11,703,429
Total operating expenses	36,194,129	29,543,719
Operating loss	(36,194,129)	(28,985,055)
Other (expense) income	(8,213)	38,763
Loss on derivative instruments	(694,858)	(349,078)
Warrant inducement expense	0	(805,753)
Other non-operating gain	1,685,379	887,604
Interest expense, net	(1,149,288)	(1,041,725)
Net loss	(36,361,109)	(30,255,244)
Modification of warrants	(350,861)	(21,734)
Net loss available to common shareholders	$ (36,711,970)	$ (30,276,978)
Net loss per common share - basic	$ (0.90)	$ (0.82)
Weighted average common shares outstanding - basic	40,662,137	36,759,115
Net loss per common share - diluted	$ (0.93)	$ (0.82)
Weighted average common shares outstanding - diluted	40,694,248	36,759,115